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ImpactsIsrael's geographic location places Israeli citizens at risk for MERS‐CoV infection. To date, MERS‐CoV‐related illness has not been reported in Israel.Dromedary camels are one potential source of human MERS‐CoV infection; the seroprevalence of MERS‐CoV‐specific antibodies in Israeli dromedary camels is unknown.In this study, MERS‐CoV seroprevalence in dromedary camels was 72% across four farms in Israel. The high prevalence of MERS‐CoV antibodies in camels and the absence of human MERS cases suggest that there is much to be learned about camel‐to‐human transmission of MERS‐CoV.

1. INTRODUCTION {#zph12482-sec-0002}
===============

Middle East respiratory syndrome coronavirus, MERS‐CoV, a member of the Betacoronavirus genus lineage C, was first identified in Saudi Arabia in 2012. As of January 29, 2018, there were 2,123 laboratory‐confirmed human MERS‐CoV cases reported to WHO, including at least 740 MERS‐CoV‐related deaths (WHO, [2018](#zph12482-bib-0018){ref-type="ref"}). Multiple studies suggest that dromedary camels are a major source for human MERS‐CoV infection. MERS‐CoV‐specific antibodies have been detected in the serum of dromedary camels across Northern Africa, including Tunisia, Egypt, Sudan, Ethiopia, Nigeria, Kenya and Somalia, and across the Arabian Peninsula, including Jordan, Saudi Arabia, Qatar, Oman and United Arab Emirates (Corman et al., [2014](#zph12482-bib-0004){ref-type="ref"}; Hemida et al., [2014](#zph12482-bib-0007){ref-type="ref"}; Meyer et al., [2014](#zph12482-bib-0010){ref-type="ref"}; Muller et al., [2014](#zph12482-bib-0012){ref-type="ref"}). MERS‐CoV neutralizing antibodies have been detected in 30‐year‐old archived camel serum samples, suggesting long‐term circulation of MERS‐CoV in dromedaries in this region (Muller et al., [2014](#zph12482-bib-0012){ref-type="ref"}). MERS‐CoV genome has been detected, isolated and sequenced from camel respiratory specimens in Northern Africa, Nigeria and Saudi Arabia, and from an air sample of a camel barn owned by a known MERS‐CoV‐infected human (Alagaili et al., [2014](#zph12482-bib-0001){ref-type="ref"}; Azhar et al., [2014](#zph12482-bib-0002){ref-type="ref"}; Chu et al., [2015](#zph12482-bib-0003){ref-type="ref"}; Haagmans et al., [2014](#zph12482-bib-0006){ref-type="ref"}; Raj et al., [2014](#zph12482-bib-0015){ref-type="ref"}). Genomic and epidemiologic studies comparing MERS‐CoV sequences from household clusters and camels, and of dromedary farms and human contacts in UAE (Muhairi et al., [2016](#zph12482-bib-0011){ref-type="ref"}; Paden et al., [2017](#zph12482-bib-0013){ref-type="ref"}), and of patients with corresponding MERS‐CoV‐positive camels in Saudi Arabia (Kasem et al., [2017](#zph12482-bib-0009){ref-type="ref"}) demonstrate that camels are a potential source of human MERS‐CoV infection.

Israel\'s geographic location in the Middle East, bordering Jordan where human cases have been reported and MERS‐CoV‐specific antibodies have been detected in the serum of dromedary camels, suggests Israeli citizens may be at risk for MERS‐CoV infection. However, to date, MERS‐CoV‐related illness has not been reported in Israel and the seroprevalence of MERS‐CoV‐specific antibodies in Israeli dromedary camels is unknown. The objective of this study was to determine the prevalence of MERS‐CoV seropositivity in Israeli camels.

2. MATERIALS AND METHODS {#zph12482-sec-0003}
========================

2.1. Serum samples {#zph12482-sec-0004}
------------------

Serum specimens from 71 dromedary camels across four different locations in Israel (Sites A‐D, Tables [1](#zph12482-tbl-0001){ref-type="table"} and [2](#zph12482-tbl-0002){ref-type="table"}) were collected between May and June 2013, as previously described (Rasis, Rudoler, Schwartz, & Giladi, [2014](#zph12482-bib-0016){ref-type="ref"}). Farm A (*n* = 9) was located east of Jerusalem; farms B‐D (*n* = 15, 27 and 20, respectively) were located in the Negev desert, in southern Israel. The origin of these camels prior to their association with these four locations is unknown. These camels were used in the tourism industry. This study included both male (*n* = 19) and female (*n* = 52) camels ages 3 to over 20 years old. Blood samples were taken by jugular vein puncture. Serum samples were obtained on the day of collection from unclotted blood using serum separator tubes. All serum specimens were shipped to the CDC and inactivated by gamma irradiation at 5 × 10^6^ rads in a Cobalt irradiator to inactivate potential pathogens, and stored at −80°C until use. The study was approved by the Tel Aviv Sourasky Medical Center Institutional Animal Care and Use Committee (Study 18--6‐13).

###### 

Middle East Respiratory Syndrome Coronavirus (MERS‐CoV) Microneutralization and Immunofluorescence (IFA) titres in sera samples collected from dromedary camels in Israel (*n* = 35): High (≥80) neutralizing antibody titres

  Sample ID   Site   Age (years)   Sex   Microneutralization Reciprocal Titres, MERS‐CoV[a](#zph12482-note-0003){ref-type="fn"}   IFA Reciprocal Titres, MERS‐CoV[b](#zph12482-note-0004){ref-type="fn"}   IFA results, BCoV[c](#zph12482-note-0005){ref-type="fn"}
  ----------- ------ ------------- ----- ---------------------------------------------------------------------------------------- ------------------------------------------------------------------------ ----------------------------------------------------------
  1           C      10            F     25,600                                                                                   ≥10,000                                                                  Pos
  2           C      12            F     6,400                                                                                    10,000                                                                   Pos
  3           D      19            F     6,400                                                                                    8,000                                                                    Pos
  4           C      9             F     3,200                                                                                    8,000                                                                    nd
  5           D      9             F     1600                                                                                     4,000                                                                    Pos
  6           D      3             F     1600                                                                                     4,000                                                                    Pos
  7           C      8             F     1600                                                                                     4,000                                                                    nd
  8           B      15            F     800                                                                                      4,000                                                                    Pos
  9           D      12            F     640                                                                                      2,000--4,000                                                             Pos
  10          D      15            F     640                                                                                      2,000--4,000                                                             Neg
  11          D      9             F     640                                                                                      2,000                                                                    Pos
  12          D      11            F     640                                                                                      750                                                                      Pos
  13          A      20 (+)        F     640                                                                                      750                                                                      Pos
  14          C      7             F     640                                                                                      2,000--4,000                                                             nd
  15          C      7             F     640                                                                                      4,000                                                                    nd
  16          D      13            F     320                                                                                      100                                                                      Pos
  17          D      14            F     320                                                                                      100                                                                      Pos
  18          D      24            F     320                                                                                      100                                                                      Pos
  19          D      12            F     320                                                                                      100                                                                      Neg
  20          C      14            M     320                                                                                      100                                                                      Pos
  21          C      14            M     320                                                                                      100                                                                      Pos
  22          C      7             F     320                                                                                      100                                                                      nd
  23          D      9             F     160                                                                                      100                                                                      Neg
  24          D      11            F     160                                                                                      100                                                                      Pos
  25          D      8             F     160                                                                                      100                                                                      Neg
  26          B      9             F     160                                                                                      100                                                                      Pos
  27          B      10            F     160                                                                                      100                                                                      Pos
  28          C      7             F     160                                                                                      100                                                                      nd
  29          C      8             F     160                                                                                      100                                                                      Neg
  30          D      20            F     80                                                                                       100                                                                      Neg
  31          D      10            F     80                                                                                       Indeterminate[d](#zph12482-note-0006){ref-type="fn"}                     Pos
  32          D      17            F     80                                                                                       100                                                                      Pos
  33          B      9--10         F     80                                                                                       100                                                                      Pos
  34          C      7             M     80                                                                                       100                                                                      Pos
  35          C      6             F     80                                                                                       100                                                                      Pos

*Notes.* nd, not done.

In vitro microneutralization assays were performed using the Jordan strain of MERS‐CoV, beginning with a serial dilution range of 1:20--1:640. Samples with a titre ≥ 640 were further examined at serial dilutions out to 1:25,600. Microneutralization titres are reported as the dilution factor at which at least one of three independent wells completely inhibited virus infection.

Immunofluorescence assays (IFAs) were performed against the Jordan strain of MERS‐CoV, beginning at a dilution of 1:100, to a final dilution of 1:10,000.

Sera were evaluated by IFA for the presence of bovine coronavirus antibodies (BCoV) at a dilution of 1:100.

Samples were considered indeterminate when an inconclusive result was obtained by two independent evaluations at a dilution of 1:100.
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###### 

Middle East Respiratory Syndrome Coronavirus (MERS‐CoV) Microneutralization and Immunofluorescence (IFA) titres in sera samples collected from dromedary camels in Israel: Low (\<80) neutralizing antibody titres (*n* = 16)

  Sample ID   Site   Age (years)   Sex   Microneutralization Reciprocal Titres, MERS‐CoV[a](#zph12482-note-0008){ref-type="fn"}   IFA Reciprocal Titres, MERS‐CoV[b](#zph12482-note-0009){ref-type="fn"}   IFA results, BCoV[c](#zph12482-note-0010){ref-type="fn"}
  ----------- ------ ------------- ----- ---------------------------------------------------------------------------------------- ------------------------------------------------------------------------ ----------------------------------------------------------
  36          D      21            F     40                                                                                       100                                                                      Pos
  37          B      10            F     40                                                                                       Indeterminate[d](#zph12482-note-0011){ref-type="fn"}                     Pos
  38          B      17            M     40                                                                                       Indeterminate                                                            Neg
  39          B      10--12        M     40                                                                                       \<100                                                                    Neg
  40          C      8             F     40                                                                                       Indeterminate                                                            Pos
  41          C      12            M     40                                                                                       Indeterminate                                                            Indeterminate
  42          C      10            M     40                                                                                       Indeterminate                                                            Neg
  43          C      7             M     40                                                                                       100                                                                      Pos
  44          C      8             M     40                                                                                       Indeterminate                                                            Indeterminate
  45          C      11            F     40                                                                                       100                                                                      nd
  46          C      6             F     40                                                                                       \<100                                                                    nd
  47          D      8             F     20                                                                                       \<100                                                                    Pos
  48          C      12            M     20                                                                                       Indeterminate                                                            Indeterminate
  49          C      9             F     20                                                                                       \<100                                                                    Pos
  50          C      5             F     20                                                                                       \<100                                                                    Pos
  51          C      10            F     20                                                                                       \<100                                                                    nd

*Notes.*nd, not done.

In vitro microneutralization assays were performed using the Jordan strain of MERS‐CoV, beginning with a serial dilution range of 1:20--1:640. Microneutralization titres are reported as the dilution factor at which at least one of three independent wells completely inhibited virus infection.

Immunofluorescence assays (IFAs) were performed against the Jordan strain of MERS‐CoV, beginning at a dilution of 1:100, to a final dilution of 1:10,000.

Sera were evaluated by IFA for the presence of bovine coronavirus antibodies (BCoV) at a dilution of 1:100.

Samples were considered indeterminate when an inconclusive result was obtained by two independent evaluations at a dilution of 1:100.
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2.2. MERS‐CoV‐specific neutralization assays {#zph12482-sec-0005}
--------------------------------------------

MERS‐CoV‐specific neutralization (MNt) assays were performed to determine the presence of neutralizing antibodies in camel sera using the Jordan strain of MERS‐CoV (Hu/Jordan‐N3/2012), following a previously established method (Sui et al., [2004](#zph12482-bib-0017){ref-type="ref"}). Initial MNt assays were performed using a titration range from 20 to 640, and samples with MNt titres of 640 were further titrated. MNt was performed using polyclonal guinea pig anti‐bovine coronavirus (Mebus strain, NIH Biodenfense and Emerging Infections Research Resources Repository) antiserum to evaluate antibody cross‐neutralization.

2.3. Immunofluorescence assay (IFA) {#zph12482-sec-0006}
-----------------------------------

Initial IFA screening was performed using sera diluted at 1:100, following a modified, previously published protocol (Corman et al., [2012](#zph12482-bib-0005){ref-type="ref"}). Briefly, MERS‐CoV (Jordan)‐infected Vero cells slides were fixed, permeabilized, blocked with whole camel serum (Abcam, 1:10,000), incubated with serum, and stained with FITC‐conjugated llama anti‐goat IgG (H + L; Bethyl Lab, 1:100; Figure [1](#zph12482-fig-0001){ref-type="fig"}). Whole camel blocking serum was screened in the absence of specimens, to verify that blocking did not result in a false positive signal. Specimens indeterminate for the presence of MERS‐CoV antibodies were re‐screened at 1:50 and 1:100. A final indeterminate determination was made after two independent screens by IFA were indeterminate. IFA titres were determined by repeated screening with serial dilutions of camel sera, out to 1:10,000. Reactivity against BCoV Mebus strain was assessed using a commercially available BCoV‐specific IFA kit (Veterinary Medical Research and Development).

![Camel serum antibodies react to Middle East Respiratory Syndrome Coronavirus (MERS‐CoV)‐infected, fixed Vero cells by immunofluorescence assay. Vero cells were infected with MERS‐CoV (Hu/Jordan‐N3/2012, a--c), or mock‐infected (d), fixed, blocked, then incubated with sera from camels with high (a, d), low (b) or no (c) MERS‐CoV neutralizing antibodies and developed for immunofluorescence. Camel sera were determined to be positive (a, b) or negative (c, d) based on the intensity of staining against MERS‐CoV‐infected Vero cells compared to mock‐infected Vero cells (representative samples are shown). Camel sera were also tested against bovine coronavirus (BCoV)‐infected or mock‐infected MDBK cells using a commercially available test kit (Veterinary Medical Research and Development, VMRD). Shown, serum from a camel that did not react in a MERS‐CoV IFA or have MERS‐CoV neutralizing antibodies reacts to BCoV‐infected MDBK cells (e), but not mock‐infected MDBK cells (f). DAPI counterstain was used and cells were imaged using a Zeiss AxioImager microscope at 20X magnification \[Colour figure can be viewed at <http://www.wileyonlinelibrary.com/>\]](ZPH-65-749-g001){#zph12482-fig-0001}

2.4. Statistical analysis {#zph12482-sec-0007}
-------------------------

Statistical analyses were performed using Fisher\'s exact test and a *p*‐value \<0.05 was considered significant.

3. RESULTS {#zph12482-sec-0008}
==========

Fifty‐one of the 71 (71.8%) camel sera had MERS‐CoV neutralizing antibodies titres (Tables [1](#zph12482-tbl-0001){ref-type="table"} and [2](#zph12482-tbl-0002){ref-type="table"}). Thirty‐five serum samples (49.3%) had high MERS‐CoV neutralizing antibody titres ranging from 80 to 25,600 (Table [1](#zph12482-tbl-0001){ref-type="table"}) with IFA titres ranging from 100 to greater than 10,000 (Table [1](#zph12482-tbl-0001){ref-type="table"}). As MERS‐CoV neutralization titres increased to ≥640 (*n* = 15), MERS‐CoV‐specific titres determined by IFA also increased above 100. Sixteen of the 71 (22.5%) camels had lower MERS‐CoV serum neutralizing antibody titres, ranging from 20 to 40 (Table [2](#zph12482-tbl-0002){ref-type="table"}). For these 16 camels, the IFA titres were equal to 100 for three camels (Table [2](#zph12482-tbl-0002){ref-type="table"} and Figure [1](#zph12482-fig-0001){ref-type="fig"}b), less than 100 for six camels, and indeterminate for the remaining seven camels. For the remaining 20 (28.2%) camels, serum neutralizing antibody titres were less than 20 or below the level of detection, with MERS‐CoV antibody titres, by IFA, either \<100 (*n* = 15; Figure [1](#zph12482-fig-0001){ref-type="fig"}c) or indeterminate (*n* = 5; data not shown). Attempts to detect coronavirus genomic material by RT‐PCR from the camel sera were unsuccessful. The inability to detect genomic material may in part be due to three key factors in this study; one, specimen collection was not optimized for nucleic acid preservation; two, prior to study, sera were irradiated at 5 × 10^6^ rads upon arrival at the CDC per importation requirements; and three, camels may not have had acute infections at the time of serum collection.

The presence of BCoV‐reactive antibodies was determined in a randomly selected subset of camel sera with MERS‐CoV neutralizing antibody titres (*n* = 42) and with no titres (*n* = 20) by BCoV IFA, using a 1:100 dilution of camel sera. Nine of 42 (21.4%) camels with MERS‐CoV microneutralization titres were negative for BCoV‐reactive serum antibodies, including one camel with a MERS‐CoV‐specific neutralization titre of 640, three were indeterminate (7%) with the remaining 30 sera (71.4%) demonstrating reactivity to BCoV. Fourteen of the 20 camels (70%) with no detectable MERS‐CoV neutralizing antibody titres (titres \<20) were positive for BCoV‐reactive antibodies at a 1:100 dilution. Serum antibodies from dromedary camels in Saudi Arabia demonstrated reactivity to both MERS‐CoV and bovine coronavirus (BCoV) (Hemida et al., [2013](#zph12482-bib-0008){ref-type="ref"}; Perera et al., [2013](#zph12482-bib-0014){ref-type="ref"}), suggesting that the presence of BCoV antibodies may impair the ability to specifically detect MERS‐CoV‐specific antibodies. However, antibodies specific to MERS‐CoV did not neutralize BCoV or SARS‐CoV infection, nor did BCoV‐specific antibodies neutralize MERS‐CoV infection (Hemida et al., [2013](#zph12482-bib-0008){ref-type="ref"}; Perera et al., [2013](#zph12482-bib-0014){ref-type="ref"}). Consistent with those findings, antiserum against BCoV did not cross‐neutralize MERS‐CoV in the Mnt used in this study, confirming the specificity of the assay to discriminate between the two viruses (data not shown).

There was no association of MERS‐CoV neutralizing antibodies with gender or age of the camels. By location, the number of MERS‐CoV neutralizing antibody positive camels was significantly higher at sites C and D (*p* = 0.008 and 0.002, respectively), compared to site B, significantly higher at site C than A (*p* \< 0.001) and significantly higher at site D than A (*p* \< 0.001). Of those specimens tested for BCoV, all indeterminate specimens (*n* = 12) originated from site D and were all positive for antibodies against MERS‐CoV.

4. DISCUSSION {#zph12482-sec-0009}
=============

These findings demonstrate high MERS‐CoV‐specific neutralizing antibody titres suggest that MERS‐CoV, or a related virus, has circulated through dromedary camels in Israel, extending the known geographic range of MERS‐CoV circulation in camels. While the results do not rule out antibody cross‐reactivity, the inability of BCoV immune sera to neutralize MERS‐CoV suggests that the presence of BCoV‐specific antibodies did not appear to impact the ability to specifically detect MERS‐CoV‐specific by Mnt. The circulation of MERS‐CoV or a closely related virus in dromedary camels in Israel in the absence of any reported clinical cases of MERS‐CoV in the Israeli population suggests that there may be other factors involved in the dynamics of camel‐to‐human transmission of MERS‐CoV beyond circulation within camel herds.
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